Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627317 | 0.90 | ESR1 (0.48) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4628430 | 0.90 | ESR1 (0.48) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4627130 | 0.90 | ESR1 (0.48) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4625668 | 0.90 | ESR1 (0.48) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4628596 | 0.90 | ESR1 (0.48) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4627003 | 0.90 | ESR1 (0.63) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4626773 | 0.88 | TSHR (0.65) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL11740048 | 0.86 | ESR1 (0.63) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4627085 | 0.86 | ESR1 (0.44) | ESR1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4625669 | 0.85 | ESR1 (0.58) | ESR1TSHRTDP1L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1188739-B1 | PHTHALIC DIESTER DERIVATIVES AND ELECTRON DONORS | TOHO TITANIUM CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1209172-B1 | SOLID CATALYST COMPONENT AND CATALYST FOR OLEFIN POLYMERIZATION | TOHO TITANIUM CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-6770586-B2 | Solid catalyst component and catalyst for olefins polymerization | TOHO TITANIUM CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-6670497-B2 | Dialkyl (at least one of which is a C4-8 tertiary alkyl) ester of an alkyl- or halo-substituted phthalic acid; used in an olefin polymerization catalyst | TOHO TITANIUM CO., LTD. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030130109-A1 | Solid catalyst component and catalyst for olefins polymerization | TOHO TITANIUM CO., LTD (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030036594-A1 | Phthalic diester derivatives and electron donors | TOHO TITANIUM CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| EP-1209172-A1 | SOLID CATALYST COMPONENT AND CATALYST FOR OLEFIN POLYMERIZATION | Toho Titanium Co., Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1188739-A1 | PHTHALIC DIESTER DERIVATIVES AND ELECTRON DONORS | TOHO TITANIUM CO., LTD. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036594-A1 | Phthalic diester derivatives and electron donors | HPD, ETFA, PPOX | ESR1 168/4885TSHR 4817/4885TDP1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.